高级检索
当前位置: 首页 > 详情页

Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pharmacy, Peking University Third Hospital, Beijing, China [2]School of Pharmaceutical Science, Peking University, Beijing, China [3]Department of Health Research Methods,Evidence, and Impact, McMaster University, Hamilton, Canada [4]Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China [5]Departmentof Respiratory Medicine, Peking University Third Hospital, Beijing, China [6]Department of Pharmacy, Peking Union Medical College Hospital, Beijing, China [7]Department of Respiratory and CriticalCare Medicine, Chinese People’s Liberation Army General Hospital, Beijing, China [8]Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China [9]Chinese GRADE Center, Lanzhou, China [10]Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China [11]Institute of Antibiotics, Huashan Hospital affiliated with Fudan University,Shanghai, China [12]Department of Pharmacy, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China [13]Clinical Trial Center of Beijing Jishuitan Hospital, Beijing, China [14]Department ofPharmacy, First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China [15]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China [16]Department of Pharmacy, Peking University People’s Hospital, Beijing, China [17]Drug Security Center, Chinese People’s Liberation Army General Hospital, Beijing, China [18]Instituteof Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China [19]Department of Pharmacy, Beijing Hospital, Beijing, China [20]Department of Pharmacy, Shanghai Chest Hospital,Shanghai Jiao Tong University, Shanghai, China [21]Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China [22]Department of Pharmacy, Shanghai FirstPeople’s Hospital, Shanghai, China [23]Department of Pharmacy, National Children’s Medical Center/Children’s Hospital of Fudan University, Shanghai, China [24]Institute of Clinical Pharmacology,Peking University First Hospital, Beijing, China [25]Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou, China [26]Department of Respiratory and Critical Care Medicine,Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China [27]Department of Respiratory and Critical Care Medicine, Beijing Hospital, National Centerof Gerontology, Beijing, China [28]Department of Pharmacy, Sichuan Provincial People’s Hospital, Chengdu, China [29]Department of Pediatrics, Peking University First Hospital, Beijing, China [30]Laboratory of Clinical Pharmacology, Chinese People’s Liberation Army General Hospital, Beijing, China [31]Department of Pharmacy, Xijing Hospital, Xi’an, China [32]Department of Pharmacy, 306thHospital of People’s Liberation Army, Beijing, China [33]Department of Pharmacy, Lanzhou University First Hospital, Lanzhou, China [34]Department of Laboratory Medicine, Peking Union MedicalCollege Hospital, Chinese Academy of Medical Sciences, Beijing, China [35]Center for Clinical Epidemiology, Peking University Third Hospital, Beijing, China [36]Department of Pharmacy, BeijingTongren Hospital, Beijing, China [37]Nursing Department, Peking University Third Hospital, Beijing, China [38]Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China [39]Pharmacy Department, First Affiliated Hospital of Kunming Medical University, Kunming, China [40]Department of Pharmacy, Beijing Children’s Hospital, Capital Medical University, Beijing, China [41]Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China [42]Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Cheeloo College of Medicine,Shandong University, Jinan, China [43]Pharmacy Department, Beijing Tiantan Hospital, Beijing, China [44]Department of Pediatrics, Peking University Third Hospital, Beijing, China [45]Center forEvidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China
出处:
ISSN:

摘要:
Clinical practice guidelines or recommendations often require timely and regular updating as new evidence emerges, because this can alter the risk-benefit trade-off. The scientific process of developing and updating guidelines accompanied by adequate implementation can improve outcomes. To promote better management of patients receiving vancomycin therapy, we updated the guideline for the therapeutic drug monitoring (TDM) of vancomycin published in 2015. Our updated recommendations complied with standards for developing trustworthy guidelines, including timeliness and rigor of the updating process, as well as the use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. We also followed the methodology handbook published by the National Institute for Health and Clinical Excellence and the Spanish National Health System. We partially updated the 2015 guideline. Apart from adults, the updated guideline also focuses on pediatric patients and neonates requiring intravenous vancomycin therapy. The guideline recommendations involve a broadened range of patients requiring TDM, modified index of TDM (both 24-hour area under the curve and trough concentration), addition regarding the necessity and timing of repeated TDM, and initial dose for specific subpopulations. Overall, 1 recommendation was deleted and 3 recommendations were modified. Eleven new recommendations were added, and no recommendation was made for 2 clinical questions. We updated an evidence-based guideline regarding the TDM of vancomycin using a rigorous and multidisciplinary approach. The updated guideline provides more comprehensive recommendations to inform rational and optimized vancomycin use and is thus of greater applicability. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 传染病学 1 区 微生物学 2 区 免疫学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 传染病学 1 区 微生物学 2 区 免疫学
JCR分区:
出版当年[2020]版:
Q1 MICROBIOLOGY Q1 IMMUNOLOGY Q1 INFECTIOUS DISEASES
最新[2023]版:
Q1 IMMUNOLOGY Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Pharmacy, Peking University Third Hospital, Beijing, China [2]School of Pharmaceutical Science, Peking University, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [*1]Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)